Product logins

Find logins to all Clarivate products below.


Dialysis Access Treatment Devices | Market Insights | Europe | 2022

The COVID-19 pandemic has had a negative impact on the European dialysis access treatment device market in 2020 and to some extent in 2021. Once the market stabilizes, the dynamic nature of the market, the launch of novel and innovative premium-price products backed by clinical data, and improvement in reimbursement will lead to steady growth through the remainder of forecast period. However, revenue growth will be limited to some extent due to increasing price competition and ongoing cost constraints in the region.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for dialysis access treatment products in Europe across an 11-year period.

Related Medtech Insights Reports

Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2035, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…
Report
Aortic Repair Devices – Market Insights – Europe
The European aortic stent graft market is the primary driver of growth in the aortic repair device market and will drive revenue expansion over the forecast period, supported by ongoing innovation…
Report
Interventional Cardiology Devices – Market Insights – Europe
The European interventional cardiology device market is highly competitive and poised for moderate growth over the forecast period, driven by increasing PCI volumes for complex CAD cases and the…
Report
Dental Implants – Market Insights – Europe
The European dental implant market is projected to experience modest expansion through 2035. Growth is driven by an aging population with ongoing long-term restorative needs, a persistent burden of…
Report
Diabetes Care Devices – Market Insights – Europe
The European diabetes care device market will grow moderately over the forecast period, driven by a rising diabetes population, favorable reimbursement policies, ongoing device innovation, and the…